Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

President Donald J. Trump underwent his annual physical examination at Walter Reed National Military Medical Center, as ...

A young man’s undiagnosed acromegaly leads to severe cardiac complications, highlighting the genetic links and diagnostic ...

Researchers from Rutgers Health and RWJBarnabas Health have developed an artificial intelligence (AI) technology that ...

An ejection fraction >35% is unconventional to be considered ... EF ≥40% with diastolic dysfunction evidence on echocardiogram, exercise for ≥3 minutes on treadmill Valsartan titrated to ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...